Curated News
By: NewsRamp Editorial Staff
March 03, 2026
NeuroOne Appoints David Wambeke as CBO with Major Personal Stock Investment
TLDR
- NeuroOne gains competitive edge by hiring David Wambeke, who brings capital markets expertise and purchased 1 million shares, signaling strong growth potential for investors.
- David Wambeke will lead NeuroOne's drug delivery program, oversee investor relations, and advance clinical development through strategic partnerships and business development initiatives.
- NeuroOne's technology aims to improve surgical outcomes for neurological disorders, potentially reducing hospitalizations and enhancing patient care through innovative medical solutions.
- David Wambeke, a Purple Heart recipient and former Army officer, joins NeuroOne after leading a successful Phase 2 pregnancy disorder trial at DiaMedica.
Impact - Why it Matters
This leadership appointment with substantial personal investment represents a significant vote of confidence in NeuroOne's growth strategy and technology platform. For patients suffering from neurological disorders, this development could accelerate the availability of innovative surgical treatments that combine diagnostic and therapeutic functions, potentially reducing hospitalizations and improving outcomes. For investors, Wambeke's capital markets expertise and track record of creating shareholder value at DiaMedica Therapeutics suggest he may enhance NeuroOne's market communication and strategic partnerships. The medical technology sector benefits when experienced leaders with both clinical and financial acumen join companies at pivotal moments, as they can bridge the gap between innovative technology development and successful commercialization. This move comes at a time when neurological disorder treatments are advancing rapidly, with companies like NeuroOne positioned to address significant unmet medical needs through minimally invasive solutions.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on transforming surgical diagnosis and treatment of neurological disorders, has announced a significant leadership appointment with strong financial commitment. David Wambeke, a proven healthcare leader with extensive capital markets expertise, has joined the company as Chief Business Officer and simultaneously purchased 1,000,000 shares of NeuroOne common stock at $0.6704 per share. This personal investment of approximately $670,400 signals strong conviction in the company's strategic growth trajectory and aligns his interests directly with shareholders.
Mr. Wambeke brings a unique combination of public company experience, capital markets expertise, and operational execution skills to NeuroOne. He will lead the company's drug delivery program while overseeing investor relations and strategic business development initiatives. His background includes serving as Chief Business Officer at DiaMedica Therapeutics, where he led the strategic expansion of their lead biologic into preeclampsia, and approximately 16 years at Craig-Hallum Capital Group in life sciences investment banking. NeuroOne's CEO Dave Rosa emphasized that Wambeke will be instrumental in sharpening messaging, deepening investor engagement, and advancing business development activities that support long-term value creation.
NeuroOne has established a strong commercial foundation with four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, primarily in epilepsy and trigeminal nerve applications. The company markets minimally invasive, high-definition electrode technology through its Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System product families. Looking ahead, Wambeke identified significant growth opportunities in basivertebral ablation, drug delivery, and spinal cord stimulation. The company also granted him an inducement stock option for 500,000 shares as part of his compensation package. For more information about NeuroOne's innovative medical technology platform, visit nmtc1.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne Appoints David Wambeke as CBO with Major Personal Stock Investment
